<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/815C5EC7-FEF6-4146-BF01-A7601535C8A3"><gtr:id>815C5EC7-FEF6-4146-BF01-A7601535C8A3</gtr:id><gtr:name>University of Montreal</gtr:name><gtr:address><gtr:line1>3000, chemin de la Cote-Sainte-Catherine</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/DE37CF26-FB6D-475D-864F-90EB49794D38"><gtr:id>DE37CF26-FB6D-475D-864F-90EB49794D38</gtr:id><gtr:name>HB Innovations Ltd, Newcastle upon Tyne</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:department>Institute of Cellular Medicine</gtr:department><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/815C5EC7-FEF6-4146-BF01-A7601535C8A3"><gtr:id>815C5EC7-FEF6-4146-BF01-A7601535C8A3</gtr:id><gtr:name>University of Montreal</gtr:name><gtr:address><gtr:line1>3000, chemin de la Cote-Sainte-Catherine</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/DE37CF26-FB6D-475D-864F-90EB49794D38"><gtr:id>DE37CF26-FB6D-475D-864F-90EB49794D38</gtr:id><gtr:name>HB Innovations Ltd, Newcastle upon Tyne</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8"><gtr:id>D97BD78E-DF6B-4FC6-8F27-BF3A5DA3EDD8</gtr:id><gtr:name>University of Ottawa</gtr:name><gtr:address><gtr:line1>550 Cumberland</gtr:line1><gtr:line4>Ottawa</gtr:line4><gtr:line5>Ontario K1N 6N5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A179E2C-FB5E-4836-AA80-6301F4DD5AB6"><gtr:id>4A179E2C-FB5E-4836-AA80-6301F4DD5AB6</gtr:id><gtr:name>University of Sydney</gtr:name><gtr:address><gtr:line1>University of Sydney</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F6E80C4E-58A9-4C0D-8EC3-1EC385FE7AD5"><gtr:id>F6E80C4E-58A9-4C0D-8EC3-1EC385FE7AD5</gtr:id><gtr:firstName>Margaret</gtr:firstName><gtr:otherNames>Fiona</gtr:otherNames><gtr:surname>Bassendine</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6D1D6A61-91DB-4223-BB27-2D6366831BFA"><gtr:id>6D1D6A61-91DB-4223-BB27-2D6366831BFA</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Taylor-Robinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/65B235DD-5088-43B0-845F-F671302B7596"><gtr:id>65B235DD-5088-43B0-845F-F671302B7596</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Dermot</gtr:otherNames><gtr:surname>Neeley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8EE81D66-AD0E-4447-AA0B-BC2982D95B82"><gtr:id>8EE81D66-AD0E-4447-AA0B-BC2982D95B82</gtr:id><gtr:firstName>Geoffrey</gtr:firstName><gtr:surname>Toms</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DA5DD1E9-3137-48CD-AE64-18256E25B8F8"><gtr:id>DA5DD1E9-3137-48CD-AE64-18256E25B8F8</gtr:id><gtr:firstName>Howard</gtr:firstName><gtr:otherNames>C</gtr:otherNames><gtr:surname>Thomas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0502028"><gtr:id>2F2C5086-5918-4F77-A892-3BE0F33D5718</gtr:id><gtr:title>Hepatitis C virus/ host lipid metabolism interaction: a novel application for lipid-modulating agents?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0502028</gtr:grantReference><gtr:abstractText>Hepatitis C virus is responsible for persistent infection in up to 500,000 people in the UK and 170 people million worldwide and is associated with both cirrhosis and liver cancer. Current treatment regimes are effective in only 50% of patients overall. Chronic HCV infection results in, often severe, disruption of the liver?s ability to regulate the secretion and storage of fats and in insensitivity to insulin which may, in some cases, result in diabetes. Fats traffic round the body in lipoprotein coated particles which are secreted from liver cells and taken up either by other liver cells or cells in other parts of the body. Accumulating evidence suggests that HCV highjacks the production of host lipoprotein particles in infected cells to produce hybrid particles which contain both virus and host lipoproteins and can gain entry to fresh cells by the normal lipoprotein pathways. This may give some protection against host antibody responses and facilitate persistence of the virus. We suggest that the disruption of host fat metabolism is a side effect of this process. If so, we should be able to demonstrate that the degree of disturbance of host metabolism is correlated to the level of secretion of hybrid virus/lipoprotein particles and is reversed on clearance of the virus by conventional antiviral therapy. Experiments are planned which will test this correlation. The hypothesis also predicts that the treatment of HCV infected patients with lipid lowering agents should reduce both virus secretion and disturbances of fat metabolism. Here we propose to test the efficacy of two such agents, polyunsaturated fatty acids and statins. Both of these agents have been shown to inhibit the replication of the virus in cell culture systems. They are relatively inexpensive and safe and are both existing therapies used extensively in the prevention heart disease. If efficacious, their application to HCV infections would have a major impact upon chronic liver disease in the short to medium term.</gtr:abstractText><gtr:technicalSummary>Hepatitis C virus is responsible for persistent infection in up to 500,000 people in the UK and 170 million worldwide and is associated with both cirrhosis and liver cancer. Current treatment regimes are effective in only 50% of patients overall. There is accumulating evidence supporting a profound effect of HCV replication on lipid metabolism and insulin resistance. Data indicates that, in vivo, infectivity is largely associated with virus/host lipoprotein complexes, termed lipo-viro-particles (LVP). These resemble host VLDL and are intimately associated with apoB and apoE. Entry into hepatocytes can be mediated by interaction of the host lipoproteins with cell surface receptors (LDLr and SR-B1) and patients with the apoE isoform (E2) which binds poorly to LDLr are more likely to clear infection. Our hypothesis is that HCV hijacks the VLDL pathway, to produce LVP and that the more HCV-LVP that are produced, the greater the disturbance in host lipids (decrease in serum cholesterol, triglycerides, apoB and increase in hepatic lipid) and insulin resistance. Thus disturbance in metabolic parameters would be expected to be greater in those with higher LVP load. Conversely pharmacological intervention to decrease the hepatic secretion of VLDL would be expected to decrease LVP load.

This has clearly raised the question whether lipid lowering agents, such as Omega-3 PUFAs and/or statins, which have been shown in vitro to inhibit HCV RNA replication, may be beneficial in vivo. Fish oils are safe, well tolerated and have long been known to reduce VLDL concentrations and heart disease risk. They are therefore an attractive candidate to evaluate in chronic hepatitis C infection and could potentially be used alone to slow progression of fibrotic liver disease or in combination with statins. 

Here, we propose a two part study in part A of which, we propose experiments to evaluate whether PUFAs and/or statins show a trend towards efficacy in patients with chronic HCV. In part B, we will collect information that can be used to support or refute the underlying hypothesis that HCV replication within the liver cell commandeers the hepatic VLDL production pathway. We will characterize LVP by size, density, host lipoprotein and viral protein content in order to establish their precise relationship to the host lipoprotein cascade. We will also evaluate the effects of HCV infection upon the kinetics of VLDL metabolism, using a stable label technique, studying patients both before and after clearance of virus infection by interferon/ribavirin treatment.</gtr:technicalSummary><gtr:fund><gtr:end>2011-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>835977</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Montreal</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Proprotein Convertase Subtilisin Kexin type 9 (PCSK9): a key molecule in the regulation of LDL receptor (LDLr)</gtr:description><gtr:id>F0304609-B1A3-44EA-888D-4C5AADDB1C70</gtr:id><gtr:impact>Initial results have been presented at the 16th International Symposium on Hepatitis C Virus and Related Viruses, held in Nice (October 2009). The manuscript is in preparation.</gtr:impact><gtr:outcomeId>4667FF4F91A-1</gtr:outcomeId><gtr:partnerContribution>Access to an assay for PCSK9 which was not commercially available and to data on PCSK9 in healthy volunteers.</gtr:partnerContribution><gtr:piContribution>The LDL receptor (LDLr) is a candidate receptor for hepatitis C virus. PCSK9 has recently been identified as a key molecule in the regulation of cell surface expression of LDLr. Prof J Davignon have developed an ELISA assay for measurement of serum PCSK9 so we established a collaboration in order to measure this key enzyme in our cohort of well characterised patients with chronic hepatitis C infection. This assay is informative for LDL turnover which we are investigating in the apolipoprotein B kinetics component of this grant</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sydney</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>Multi-centre genome-wide association study of response to treatment in chronic hepatitis C</gtr:description><gtr:id>D86E3CEB-010A-4FC5-B991-EAE436B69AFA</gtr:id><gtr:impact>This has so far resulted in a Nature Genetics publication from the CHC genotype 1 group ( PMID 19749756) and 2 further 2011 publications. It is anticipated that further publication(s) will follow from this collaboration</gtr:impact><gtr:outcomeId>C2A909C9994-1</gtr:outcomeId><gtr:partnerContribution>Professor J George approached us to participate in this genome-wide association study of treatment response in chronic hepatitis C; he was aware of our MRC experimental medicine grant and hence knew we had a large well characterised cohort of patients for inclusion in the multi-centre study.</gtr:partnerContribution><gtr:piContribution>One of the centres that contributed DNA and phenotying of chronic hepatitis C (CHC) patients to this study. We have contributed material from both CHC genotype 1 and CHC genotype 3.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ottawa</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Assessment of hepatitis C virus associated with apolipoprotein B48</gtr:description><gtr:id>056BC06B-094E-4C83-B8F3-6CE6D62E4724</gtr:id><gtr:impact>Publication in Gastroenteroloogy</gtr:impact><gtr:outcomeId>8FD4AE17AE1-1</gtr:outcomeId><gtr:partnerContribution>Access to reagents and expertise in the biochemistry of apolipoprotein B100 and B48, which are the structural proteins of VLDL and chylomicrons.</gtr:partnerContribution><gtr:piContribution>It is widely accepted that infectious HCV associates with apolipoprotein (apo) B100 but controversial whether it associates with apoB48. We established this collaboration in order to access reagents that are able to distinquish between apoB100 and apoB48.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>College of Medical and Dental Sciences</gtr:department><gtr:description>Iodixanol density gradient analysis of HCVcc</gtr:description><gtr:id>0A5B7D2A-DA20-45AD-8F9F-0A010CDB2384</gtr:id><gtr:impact>Our data showed for the first time that low density HCV is less susceptible to neutralisation by patient antibodies. Co-authorship of publication [PMID 18829747].</gtr:impact><gtr:outcomeId>4EF2D8F5E4B-1</gtr:outcomeId><gtr:partnerContribution>This collaboration was to analyse HCVcc in iodixanol density gradients before and after &amp;quot;neutralisation&amp;quot; with pooled chronic hepatitis C patient IgG. Professor Mckeating aproached us in view of our expertise in this methodology.</gtr:partnerContribution><gtr:piContribution>Iodixanol gradient analysis of HCV RNA derived from HCVcc.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>HB Innovations Ltd, Newcastle upon Tyne</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Diagnostic test to measure hepatitis C lipo-viral particles</gtr:description><gtr:id>41171094-A84C-4A6F-931A-AC1840A26DD8</gtr:id><gtr:impact>Still in development.</gtr:impact><gtr:outcomeId>KsTbCSjEWfc-1</gtr:outcomeId><gtr:piContribution>We have developed an assay for hepatitis C lipo-viral particles which could be more clinically useful that HCV total viral load. We have entered into this colloboration to simplify and commercialise the assay.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Hepatitis Nurse specialists regional forum</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>E513F486-DEFF-4818-ACD3-51153DCFA28A</gtr:id><gtr:impact>Presentation about options for anti-viral treatment non-responders, including our pilot study.

Increased awareness.</gtr:impact><gtr:outcomeId>55A078821C1</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>LIVErNORTH - Newcastle patient support group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>7422FA18-7807-4088-BD83-BBD991B99B73</gtr:id><gtr:impact>Presentation of future treatment options in hepatitis C and of our research using lipid modulating agents

Increased awareness and participation in studies</gtr:impact><gtr:outcomeId>58C995F7559</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The clinical trial featured in the Hepatitis C Trust website (http://www.hepctrust.org.uk/news/2009/March/Hepatitis+C+patients+who+have+failed+treatment+needed+for+UK+trial+using+fish+oils+and+statins.htm)</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>24E1C072-8BB3-445D-9B9D-C0DB94787B6F</gtr:id><gtr:impact>Dissemination of details of the trial to the major UK patient group

Improved recruitment to the trial.</gtr:impact><gtr:outcomeId>64DE74B2964</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.hepctrust.org.uk/news/2009/March/Hepatitis+C+patients+who+have+failed+treatment+needed+for+UK+trial+using+fish+oils+and+statins.htm</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50212</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Newcastle Healthcare Charity</gtr:department><gtr:description>Project grant</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>Newcastle upon Tyne Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>JAG/ML/0712</gtr:fundingRef><gtr:id>634DE43A-02F4-4BF9-A927-2297CCF36DA0</gtr:id><gtr:outcomeId>Jsjib1tBBfR</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1924918</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>HCV Research UK Resource Consortium project</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>C0365</gtr:fundingRef><gtr:id>C7F6122D-18DC-40F0-8582-675C667D7648</gtr:id><gtr:outcomeId>UZoayxKPqbZ</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>HCV particles in serum transfer onto triglyceride rich lipoproteins including lipid emulsion(s). This is the first demonstration of an intravascular phase of the HCV life-cycle. This may be exploited therapeutically.</gtr:description><gtr:grantRef>G0502028</gtr:grantRef><gtr:id>07539DB2-5908-4CCE-8D31-778222FF99BC</gtr:id><gtr:impact>UK patent [GB0915957.5] was filed recently and developmental work is in progress.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>B7E5E747DC1</gtr:outcomeId><gtr:patentId>GB0915957.5</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>The use of lipid emulsions for binding hepatitis C virus</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Genetic variants in IL28B and hepatitis C treatment outcome</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>879BF378-989C-4C7E-ACF2-96D540BA25CE</gtr:id><gtr:impact>Editorial in Nature Genetics outlining the importance of genetic variants in IL28B in individualizing treatment decisions. &amp;quot;Predictive models for HCV treatment response hold the potential to inform treatment decisions for millions of patients who are infected with HCV&amp;quot; [Nature Genetics, 41;1048-50].</gtr:impact><gtr:outcomeId>E91127C17BC</gtr:outcomeId><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>'A randomised, controlled, factorial pilot study investigating Omacor and/or Fluvastatin in patients with chronic hepatitis C who have not responded to standard combination anti-viral therapy'</gtr:description><gtr:id>333244AB-4FF4-4E19-9422-E72A7BC787BD</gtr:id><gtr:impact>Recruitment is now closed, the data is being analysed and a publication is pending.</gtr:impact><gtr:outcomeId>34B3A5A9D29</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Omacor and/or Fluvastatin</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have developed an assay for Hepatitis C lipo-viral particles and demonstrated a significant correlation with insulin resistance in patients with chronic hepatitis C genotype 1 infection. Insulin resistance is an important predictor of fibrosis progression and non-respose to anti-viral treatment. This assay has demonstrated a direct link between infectious virus and host factors.</gtr:description><gtr:id>A638D33F-CF6D-4D7E-9EF4-E6328B760347</gtr:id><gtr:impact>The assay is being used in our pilot intervention trial with lipid modulating therapy and has potential utility in future trials.</gtr:impact><gtr:outcomeId>484B72DDBC1</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Assay for Hepatitis C lipoviroparticles</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have made the novel observation that HCV can transfer onto triglyceride rich lipoproteins and lipid emulsions in vivo and in vitro. This may be used in the development of novel therapy and/or in the development of an assay to measure this previously unrecognised phase of the HCV life-cycle.</gtr:description><gtr:id>B303F011-8DA5-4461-ACBD-B529DC64B531</gtr:id><gtr:impact>UK patent application number GB0915957.5</gtr:impact><gtr:outcomeId>9EBD7A6F0FF</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>The use of lipid emulsions for binding hepatitis C virus</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Laboratory method fractionating HCV by density and assaying HCV RNA associated with apolipoprotein B, a pututative measure of more infectious HCV.</gtr:description><gtr:id>3A25C353-9701-4DD3-8625-C4FCAD0218F3</gtr:id><gtr:impact>This assay is an end-point in our pilot study investigating lipid modulating agents in the treatment of HCV and has potential utility in other trials.</gtr:impact><gtr:outcomeId>D14DD71D348</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Assay for hepatitis C virus lipo-viral particles</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Clinical, biochemical and virological data on all patients with chronic hepatitis C recruited into research studies funded by this grant.</gtr:description><gtr:id>BCE29568-26CD-4717-B951-813B33591344</gtr:id><gtr:impact>This allows coordinated and standised data collection between multiple sites. Currently 2 centres are entering data but it can be expanded in future, e.g. for a multi-centre clinical trial.</gtr:impact><gtr:outcomeId>F8199CF8A68</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Database of HCV host lipid study in Symphony, a web-based electronic data capture system</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>93E1098C-5AC7-4DF7-B6C9-7CBEED1E71B6</gtr:id><gtr:title>Transient elastography for the assessment of chronic liver disease: ready for the clinic?</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b41ed5756913a8115ec4ee278021cd"><gtr:id>b2b41ed5756913a8115ec4ee278021cd</gtr:id><gtr:otherNames>Cobbold JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>9514FF041B6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49E600C4-B96B-453F-8001-D85ADA130DB8</gtr:id><gtr:title>Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a0f188fed10c460081464effae289ad"><gtr:id>1a0f188fed10c460081464effae289ad</gtr:id><gtr:otherNames>Bridge SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>Br1KEemb9sE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EFBBA85-4C9F-4D42-AEAE-511286E6C845</gtr:id><gtr:title>Characterization of hepatitis C RNA-containing particles from human liver by density and size.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc752d0d24a4c5056a0b56952dea2765"><gtr:id>bc752d0d24a4c5056a0b56952dea2765</gtr:id><gtr:otherNames>Nielsen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>6BF1F5069FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D52236C3-19DE-4353-BC13-90BDF2E074FD</gtr:id><gtr:title>Non-invasive means of measuring hepatic fat content.</gtr:title><gtr:parentPublicationTitle>World journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4e867ee922c1c0b6779dc22b9480cc3"><gtr:id>e4e867ee922c1c0b6779dc22b9480cc3</gtr:id><gtr:otherNames>Mehta SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1007-9327</gtr:issn><gtr:outcomeId>E6BD667A46E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7D134AC-5E25-4C44-9A38-FB9E13193F54</gtr:id><gtr:title>Immunohistochemical assessment of hepatitis C virus antigen in cholestatic hepatitis after liver transplantation.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b22c4ca01b3cb6b61a3faab95c6fa673"><gtr:id>b22c4ca01b3cb6b61a3faab95c6fa673</gtr:id><gtr:otherNames>Fenwick F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>83F7DA13487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3195F7B0-6228-48D2-B322-714B6AFFBD7A</gtr:id><gtr:title>Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency.</gtr:title><gtr:parentPublicationTitle>Metabolic brain disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f6ef20acf5fc8323fced8e2916ed6f"><gtr:id>b4f6ef20acf5fc8323fced8e2916ed6f</gtr:id><gtr:otherNames>Sheridan DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-7490</gtr:issn><gtr:outcomeId>doi_55f983983cada3a1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D46D8CB5-9DF5-48B5-8A40-DB7E25DAEBEB</gtr:id><gtr:title>Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).</gtr:title><gtr:parentPublicationTitle>Clinics and research in hepatology and gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f6ef20acf5fc8323fced8e2916ed6f"><gtr:id>b4f6ef20acf5fc8323fced8e2916ed6f</gtr:id><gtr:otherNames>Sheridan DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2210-7401</gtr:issn><gtr:outcomeId>pm_15651_21_22959093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE984F53-3DEF-47B8-A2B0-5CC588A966DD</gtr:id><gtr:title>Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b41ed5756913a8115ec4ee278021cd"><gtr:id>b2b41ed5756913a8115ec4ee278021cd</gtr:id><gtr:otherNames>Cobbold JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>0EB59BE90AA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E0BBE3F-0322-4365-B138-265F8D6AB7B5</gtr:id><gtr:title>Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3375e9a835923724668c6c34d1f7707"><gtr:id>e3375e9a835923724668c6c34d1f7707</gtr:id><gtr:otherNames>Smith KR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>M6ncHEAwEw9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4A3C483-4571-42D9-B602-1F34AA56AEBB</gtr:id><gtr:title>31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease.</gtr:title><gtr:parentPublicationTitle>AJR. American journal of roentgenology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe6364eab2f8c827eacfe5f22b8e8bfb"><gtr:id>fe6364eab2f8c827eacfe5f22b8e8bfb</gtr:id><gtr:otherNames>Lim AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0361-803X</gtr:issn><gtr:outcomeId>F91ACE86797</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C306F01-6E7C-4A0C-832E-F36EFAE410CF</gtr:id><gtr:title>Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy - a pilot randomised clinical trial.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f6ef20acf5fc8323fced8e2916ed6f"><gtr:id>b4f6ef20acf5fc8323fced8e2916ed6f</gtr:id><gtr:otherNames>Sheridan DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>pm_540e148e148706faf</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65856550-A057-4376-A08F-2F8FC5F718C3</gtr:id><gtr:title>HCV and the hepatic lipid pathway as a potential treatment target.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bcb46c4e797389fdcf7de72b31ae15f"><gtr:id>6bcb46c4e797389fdcf7de72b31ae15f</gtr:id><gtr:otherNames>Bassendine MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>qWpHWseK7BW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D33868C-DE90-4F2A-9F93-FB056A156AD8</gtr:id><gtr:title>Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus.</gtr:title><gtr:parentPublicationTitle>Transplantation proceedings</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff4ba454cd64161c5ef21b7cd45d6dec"><gtr:id>ff4ba454cd64161c5ef21b7cd45d6dec</gtr:id><gtr:otherNames>van der Laan LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0041-1345</gtr:issn><gtr:outcomeId>JbkT3L7BfWp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4F141FB-77D9-4F8E-B211-E2D29AFBB2AB</gtr:id><gtr:title>Binding of liver derived, low density hepatitis C virus to human hepatoma cells.</gtr:title><gtr:parentPublicationTitle>Journal of medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5292dfe7dacdc3f4f68dd2c4085a1b06"><gtr:id>5292dfe7dacdc3f4f68dd2c4085a1b06</gtr:id><gtr:otherNames>Martin C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0146-6615</gtr:issn><gtr:outcomeId>2CCDE0458A6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9563A18E-76DD-42DD-B7AD-ADE363F1497A</gtr:id><gtr:title>Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2b41ed5756913a8115ec4ee278021cd"><gtr:id>b2b41ed5756913a8115ec4ee278021cd</gtr:id><gtr:otherNames>Cobbold JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>937136FB94D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32A7FCB7-E07E-43B5-B5E1-5CE8851B05A3</gtr:id><gtr:title>Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40ce492da64d8686da83c7038b7e65"><gtr:id>fe40ce492da64d8686da83c7038b7e65</gtr:id><gtr:otherNames>Grove J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>DB6AA0FD3C2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F63AF69-915E-45E6-8E63-79504107A92D</gtr:id><gtr:title>IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/278cd594aae44c7f4d951e727053e926"><gtr:id>278cd594aae44c7f4d951e727053e926</gtr:id><gtr:otherNames>Suppiah V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>4A8A135DE78</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F35AC3D-9204-49C3-B7FD-CB3E2DB60C86</gtr:id><gtr:title>Improved hepatitis C treatment response in younger patients: findings from the UK HCV National Register cohort study.</gtr:title><gtr:parentPublicationTitle>Epidemiology and infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e8e11003078dfb39eeb8ebe64762c838"><gtr:id>e8e11003078dfb39eeb8ebe64762c838</gtr:id><gtr:otherNames>Harris HE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0950-2688</gtr:issn><gtr:outcomeId>pm_15651_21_22124380</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89E67373-128C-4973-B287-4DC4FE40CFF4</gtr:id><gtr:title>Intravascular transfer contributes to postprandial increase in numbers of very-low-density hepatitis C virus particles.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbbd64fcd1ea78c405e06d38e7028ccc"><gtr:id>dbbd64fcd1ea78c405e06d38e7028ccc</gtr:id><gtr:otherNames>Felmlee DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>tLufsCJufH1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8409594-680D-42BF-995F-65E7CB2D2D9F</gtr:id><gtr:title>Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a610b8cc0953c3fc751032a93b0d84f"><gtr:id>7a610b8cc0953c3fc751032a93b0d84f</gtr:id><gtr:otherNames>Price DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>991A60554FF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F34410E-C8E1-4087-9E12-18FDB1EFFC72</gtr:id><gtr:title>IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/278cd594aae44c7f4d951e727053e926"><gtr:id>278cd594aae44c7f4d951e727053e926</gtr:id><gtr:otherNames>Suppiah V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>HLv7G8n8ThA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EAD480D-A129-4903-8819-20EE01D6A8D5</gtr:id><gtr:title>Antisense technology to lower LDL cholesterol.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8c26c9307f7f24db95f4c19e4126564"><gtr:id>c8c26c9307f7f24db95f4c19e4126564</gtr:id><gtr:otherNames>Neely RD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>V8MsGYTBPFu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4A55C8B-2798-4251-83B6-3ADEF3DFBCFD</gtr:id><gtr:title>Perihepatic lymph nodes as markers of disease response in patients with hepatitis C-related liver disease: a prospective clinical evaluation.</gtr:title><gtr:parentPublicationTitle>European journal of gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b104622210575751cf85f6bc4859ba87"><gtr:id>b104622210575751cf85f6bc4859ba87</gtr:id><gtr:otherNames>Grier S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0954-691X</gtr:issn><gtr:outcomeId>A765E969911</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAEDD285-DEDF-487F-9AB6-E907478CAC76</gtr:id><gtr:title>Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f6ef20acf5fc8323fced8e2916ed6f"><gtr:id>b4f6ef20acf5fc8323fced8e2916ed6f</gtr:id><gtr:otherNames>Sheridan DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15651_21_22414761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D15BD4E-A095-4801-BE25-2D9438A390CA</gtr:id><gtr:title>Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bc752d0d24a4c5056a0b56952dea2765"><gtr:id>bc752d0d24a4c5056a0b56952dea2765</gtr:id><gtr:otherNames>Nielsen SU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>C125364AD11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F334C349-E07B-4888-8673-14B52BDD6ACC</gtr:id><gtr:title>Lipids and HCV.</gtr:title><gtr:parentPublicationTitle>Seminars in immunopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bcb46c4e797389fdcf7de72b31ae15f"><gtr:id>6bcb46c4e797389fdcf7de72b31ae15f</gtr:id><gtr:otherNames>Bassendine MF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1863-2297</gtr:issn><gtr:outcomeId>pm_15651_21_23111699</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60E84E97-13B6-4843-88CE-4B820E95859A</gtr:id><gtr:title>PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a0f188fed10c460081464effae289ad"><gtr:id>1a0f188fed10c460081464effae289ad</gtr:id><gtr:otherNames>Bridge SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>doi_55f983983cb75275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>670458FE-0992-4348-867D-5E04E0BFDF4D</gtr:id><gtr:title>Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aae18667788a4040544596264585bb82"><gtr:id>aae18667788a4040544596264585bb82</gtr:id><gtr:otherNames>Grieve R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>36B1463258F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B370EE2-9D57-4A6E-B0DD-6501027FC000</gtr:id><gtr:title>Apolipoprotein B-associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti-viral agents interferon-alpha and ribavirin.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f6ef20acf5fc8323fced8e2916ed6f"><gtr:id>b4f6ef20acf5fc8323fced8e2916ed6f</gtr:id><gtr:otherNames>Sheridan DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>4A430CC91DB</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0502028</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>